Ergomed Makes Board Changes
This article was originally published in Scrip
Ergomed Plc. has appointed current chief financial officer (CFO), Neil Clark, as fulltime CEO of the company's trading subsidiary PrimeVigilance. Neil will remain on Ergomed's board of directors and Stephen Stamp, who has been appointed as the company's CFO, will also be joining its board. Stamp has over 30 years' experience in corporate finance and general management and joins Ergomed from US-based AssureRx Health, Inc., where he was CFO. Before this, he was CFO of EZCORP, Inc., and chief operating officer and CFO of Xanodyne Pharmaceuticals, Inc. Stamp was also group finance director at Regus Plc. and prior to this he held the same position at Shire Pharmaceuticals.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.